{Reference Type}: Journal Article
{Title}: TSPO in pancreatic beta cells and its possible involvement in type 2 diabetes.
{Author}: Guillemain G;Khemtemourian L;Brehat J;Morin D;Movassat J;Tourrel-Cuzin C;Lacapere JJ;
{Journal}: Biochimie
{Volume}: 224
{Issue}: 0
{Year}: 2024 Sep 20
{Factor}: 4.372
{DOI}: 10.1016/j.biochi.2024.06.007
{Abstract}: Amyloidosis forms a large family of pathologies associated with amyloid deposit generated by the formation of amyloid fibrils or plaques. The amyloidogenic proteins and peptides involved in these processes are targeted against almost all organs. In brain they are associated with neurodegenerative disease, and the Translocator Protein (TSPO), overexpressed in these inflammatory conditions, is one of the target for the diagnostic. Moreover, TSPO ligands have been described as promising therapeutic drugs for neurodegenerative diseases. Type 2 diabetes, another amyloidosis, is due to a beta cell mass decrease that has been linked to hIAPP (human islet amyloid polypeptide) fibril formation, leading to the reduction of insulin production. In the present study, in a first approach, we link overexpression of TSPO and inflammation in potentially prediabetic patients. In a second approach, we observed that TSPO deficient rats have higher level of insulin secretion in basal conditions and more IAPP fibrils formation compared with wild type animals. In a third approach, we show that diabetogenic conditions also increase TSPO overexpression and IAPP fibril formation in rat beta pancreatic cell line (INS-1E). These data open the way for further studies in the field of type 2 diabetes treatment or prevention.